Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
|2||Active, not recruiting||
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Musculoskeletal Plasticity After Spinal Cord Injury
† Study has passed its completion date and status has not been verified in more than two years.